These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16281073)

  • 1. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.
    Rangatia J; Bonnet D
    Leukemia; 2006 Jan; 20(1):68-76. PubMed ID: 16281073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
    Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
    Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
    Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
    Brózik A; Casey NP; Hegedus C; Bors A; Kozma A; Andrikovics H; Geiszt M; Német K; Magócsi M
    Ann N Y Acad Sci; 2006 Dec; 1090():344-54. PubMed ID: 17384279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
    Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
    Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
    Wang W; Du Y; Li NN; Lv FF; Lin GQ
    Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective leukemia cell death by activation of the double-stranded RNA-dependent protein kinase PKR.
    Li YJ; Zeng JM; Huang SF; Wang XZ; Zhao SQ; Bai WJ; Cao WX; Huang ZG; Feng WL
    Int J Mol Med; 2011 Aug; 28(2):215-22. PubMed ID: 21468538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation.
    Gery S; Tanosaki S; Hofmann WK; Koppel A; Koeffler HP
    Oncogene; 2005 Feb; 24(9):1589-97. PubMed ID: 15674331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
    Wilda M; Fuchs U; Wössmann W; Borkhardt A
    Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.